Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06055738
Other study ID # TangduH-1
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date October 9, 2023
Est. completion date December 30, 2027

Study information

Verified date September 2023
Source Tang-Du Hospital
Contact Hongxi Zhao, PhD
Phone +8615094088350
Email zhaohx@fmmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, single arm, phase II clinical study to evaluate the efficacy and safety of Zimberelimab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer.


Description:

This study will enroll patients with IB3 and IIA2 locally advanced cervical cancer who received three cycles of neoadjuvant Zimberelimab combined with albumin-bound paclitaxel and cisplatin to evaluate the efficacy and safety.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date December 30, 2027
Est. primary completion date December 30, 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Voluntary participation in clinical research. 2. Age =18 years old, female. 3. Squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix confirmed by histology/cytology. 4. Previously untreated locally advancedcervical cancer (2018 FIGO stage IB3, IIA2) . 5. At least one measurable lesion was suitable for target lesion according to RECIST v1.1 . 6. Within 14 days before the first treatment, the major organ functions were basically normal. 7. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1; 8. Subjects agree to provide sufficient tumor tissue samples for PD-L1 expression detection; 9. If hepatitis B surface antigen (HBsAg) is positive and/or hepatitis B core antibody (HBcAb) is positive, hepatitis B virus DNA (HBV DNA) is detected, HBV DNA < 104 copies /ml or < 2000IU/mL can be enrolled. Or those who had received antiviral therapy for at least 4 weeks before the first dose of study drug and were willing to continue antiviral therapy during the study were eligible for enrollment. Those with HCV antibody positive should be excluded. 10. Subjects of childbearing age and their sexual partners agreed to consent to contraceptive use after signing an informed consent form, during treatment and for at least 6 months after the last dose of the study intervention. Exclusion Criteria: 1. Patients with active autoimmune disease or a history of autoimmune disease. 2. Previous history of allogeneic hematopoietic stem cell transplantation or organ transplantation (except corneal transplantation). 3. Use of immunosuppressive drugs within 14 days prior to treatment, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroids (i.e., not more than 10 mg/ day of prednisolone or another corticosteroid at the physiological dose of the drug). 4. Previous treatment with anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, or anti-lymphocyte antigen 4 (CTLA-4) antibody. 5. Arterial or venous thromboembolic events within the previous 6 months, including myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, pulmonary embolism, deep vein embolism or any other major thromboembolism, implantable venous access port or catheter-derived thrombosis, or superficial venous thrombosis. Except for patients with stable thrombus after conventional anticoagulant therapy, prophylactic use of low-dose low molecular weight heparin was allowed. 6. Previous history of gastrointestinal perforation, gastrointestinal fistula, genital fistula (such as vesicovaginal fistula, urethrovaginal fistula, vesicovaginal fistula, etc.); Patients were allowed if the perforation or fistula had been treated with diversion surgery, resection, or repair, and the disease was recovered or relieved as judged by the investigator. 7. Symptomatic congestive heart failure (New York Heart Association class II-IV) Arrhythmias with poorly controlled symptoms. 8. Active pulmonary tuberculosis, receiving anti-tuberculosis treatment. 9. Interstitial lung disease. 10. Severe infections that are active or poorly controlled clinically. Severe infection within 3 weeks before treatment, including but not limited to patients hospitalized for complications of infection, bacteremia, or severe pneumonia. 11. Central nervous system metastasis, leptomeningeal metastasis, spinal cord compression, or leptomeningeal disease. 12. Human immunodeficiency virus (HIV) infection, known syphilis infection. 13. Have received live vaccine within 4 weeks of the first use of the experimental drug, or plan to receive live vaccine during the study. 14. Known or suspected allergy to the trial drug or any drug related to the trial. 15. Pregnant or lactating women. 16. There were other conditions deemed by the investigator to be inappropriate for enrollment.

Study Design


Intervention

Drug:
Zimberelimab
240mg,d1,iv,Q21D
Albumin-bound Paclitaxel
260mg/m2,d1,iv,Q21D
Cisplatin
75mg/m2,d1,iv,Q21D

Locations

Country Name City State
China Hongxi Zhao Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Tang-Du Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate (ORR) Objective response rate based on RECIST v1.1, ORR was defined as the ratio of best complete response (CR) and partial response (PR) recorded from the start of treatment to the preoperative evaluation 3-4 months
Secondary Complete pathological response (pCR) Complete pathological response (pCR) was defined as the proportion of all surgical patients in whom no viable tumor cells were found in the resected specimen. one year
Secondary Major Pathological Response (MPR) Major pathological response (MPR) was defined as the proportion of patients with =10% residual viable tumor cells in the resected specimen among all surgical patients. one year
Secondary R0 resection rate R0 resection rate: defined as the proportion of patients undergoing surgical excision who had a negative margin of surgical specimens one year
Secondary Event-free survival (EFS) Event-free survival (EFS) was defined as the time from the start of treatment to the first occurrence of any of the following events: disease progression beyond surgical treatment, local or distant recurrence, death from any cause, etc. three years
Secondary Overall survival (OS) Overall survival (OS) : defined as the time between the initiation of treatment and death from any cause. three years
Secondary Adverse Events Based on NCI-CTC AE v5.0 three years
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03225443 - Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy N/A
Recruiting NCT06079671 - Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) Phase 3
Completed NCT05059119 - Rectovaginal Fistula in Post-Radiotherapy Advanced Cervical Cancer Patients
Recruiting NCT06156514 - Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer Phase 3
Completed NCT03298893 - Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months Phase 1/Phase 2
Withdrawn NCT01514955 - An Initial Feasibility Study to Integrate MRI Based Brachytherapy and CT/MR Fused INRT in Treatment of Advance Cervical Cancer Phase 1
Recruiting NCT05950087 - Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
Recruiting NCT04884906 - Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer Phase 2
Not yet recruiting NCT05799469 - Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer Phase 2
Recruiting NCT05311566 - PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer Phase 2
Terminated NCT02045433 - Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer Phase 2
Recruiting NCT06237257 - A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer Phase 2
Not yet recruiting NCT06288360 - Neoadjuvant Immunochemotherapy in PD-L1-negative LACC Phase 2
Not yet recruiting NCT06288373 - Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC Phase 2/Phase 3
Recruiting NCT06068387 - A Prospective Study on the Prediction Model of Para-aortic Lymph Node Metastasis N/A
Recruiting NCT05378087 - Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer N/A
Recruiting NCT03963882 - NAC Followed by RH for the Treatment of LACC Phase 2
Recruiting NCT01938105 - Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer Phase 2
Active, not recruiting NCT01793701 - Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer Phase 1/Phase 2
Completed NCT01230996 - Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer Phase 1/Phase 2